EARLY-ACCESS
MERCURIUS™
Total DRUG-seq service
Massively multiplexed and total RNA-seq directly on cell lysates - no need for prior RNA extraction. Ultra-scalable, total RNA-seq for transcriptomic profiling and target discovery.
The MERCURIUS™ Total DRUG-seq service offers a convenient and streamlined solution for full-length RNA transcriptomics projects of any size.
As part of the Total DRUG-seq service, our clients simply need to deliver to us their 96- or 384-well plates containing frozen cells.
Upon receipt, our team will start processing the plates the same week and return results in as little as three weeks.
During the process, we always keep clients informed at defined checkpoints so that we can decide together how to best proceed to the next steps.
Next-generation sequencing and data pre-processing (including alignment to the genome of choice) are part of our standard service as well. As a result, we provide our clients raw data, sequencing and alignment reports, and gene count matrices which can be used for downstream gene expression analysis.
Optional downstream differential gene expression analysis are also available upon request.
Step 1
Step 2
Step 3
Step 4
2 days
Step 5
(Qubit, Fragment analyzer, shallow sequencing)
1 week
Step 6
1 week
Step 7
Step 8
To generate high-quality sequencing data we recommend starting with 5’000 – 25’000 mammalian cells per well for 96 well-plate and 2'000 - 10'000 cells per well for 384 well-plate.
The total RNA amount per pool should be at least 80'000 cells.
MERCURIUS™ DRUG-seq can be performed on various sample types, including: Cell lines, Primary cells, Organoids or Spheroids.
Validated cells lines
Cell line/Tissue | Organism |
HT1080 SMARCA4 KO | Human |
hTEC | Human |
iPSC microglia | Human |
MCF7 | Human |
HepG2_IGF1RKO | Human |
Beas-2B | Human |
dTHP-1 | Human |
iPSC derived cardiomyocytes | Human |
Endothelial | Human |
Hepatocyte | Human |
HEPG2 | Human |
Hepatocyte | Human |
SF9 | Spodoptera |
A549 | Human |
Breast Cancer (MCF7) | Human |
B lymphoblast MM.1s. | Human |
Hek293 | Human |
HeLa Cells | Human |
U2-OS | Human |
Hek293 | Human |
dTHP-1 | Human |
AsPC-1 | Human |
PBMC (TCD4) | Human |
Skeletal muscle (LHCN-M2) | Human |
HepaRG | Human |
Macrophage (MV-4-11) | Human |
PBMCs (Blood) | Human |
Microglia | Human |
Fibroblast Like Synoviocyte donor 1502 | Human |
Fibroblast | Human |
iPSC-derived neuron | Human |
Human lung carcinoma epithelial cell line | Human |
Human breast epithelial adenocarcinoma cell line | Human |
Human liver hepatocellular carcinoma cell line | Human |
Human cardiomyocytes derived from induced pluripotent stem cells (iPSCs) | Human |
Total DRUG-seq provides comprehensive coverage of the full-length RNA transcripts.
We therefore normally recommend sequencing 10-20 million reads for each sample, depending on the project's scale and scope.
Explore the latest, relevant publications in the industry to learn more about our technologies.
Book a one-on-one call with one of our RNA experts to discover how we can assist your next project.